PORTEFEUILLE

Most cancer patients receiving immunotherapy today are treated with combinations of two drugs - a strategy that works well for many, but causes serious harm in others. A significant minority experience what we call "Biological Antagonism": adding the second drug suppresses, rather than amplifies, the immune response, leading to worse outcomes than a single, cheaper drug alone.
Eviive is developing a predictive blood test to solve this problem before treatment begins. By analyzing extracellular vesicles (EVs) - tiny particles shed by immune cells into the bloodstream - we measure two ratios across different arms of the immune system that reveal how a patient's immune network is communicating. This "live signal" can mathematically route each patient to the therapy that maximizes their survival while sparing them from unnecessary toxicity and cost. The technology is being developed in collaboration with leading Swiss hospitals and global pharmaceutical partners.

Using support from the Gebert Rüf Stiftung, Eviive analyzed a cohort of 124 metastatic melanoma patients (USZ) treated with PD-1 and/or CTLA-4 inhibitors. From this discovery cohort, we identified a high-risk subgroup - the "Harm Zone" - representing 13% of patients, defined by two blood-based immune communication ratios.
The findings are striking: within this subgroup, patients routed to monotherapy showed a 100% response rate (7/7), while patients who received the combination therapy showed a response rate of only 33% (3/9; Fisher p=0.011). The survival difference is equally stark - patients in the Harm Zone on combination therapy progressed in as little as 3 months, while those on monotherapy have not yet reached their median progression time.
Critically, the signal has been stress-tested using Leave-One-Out Cross-Validation across all 13 iterations - zero failures - confirming robustness against individual outliers. These findings are exploratory and hypothesis-generating; all cut-points are data-optimized in this discovery cohort, and prospective external validation is required before clinical use.
This data forms the scientific foundation for a German validation cohort currently being established (N=80, University Medical Center Hamburg-Eppendorf), active pilot discussions with pharma partners including Roche and Merck, and a seed financing round currently underway to advance Eviive from research spin-off to clinical-stage diagnostic company.